Therefore, in isolation, TRUS is inaccurate for prostate cancer detection and is not beneficial for this purpose [65]. Variant 2: Clinically suspected prostate cancer. Negative TRUS-guided biopsy. Initial diagnosis. Next imaging study. Bone Scan Whole Body There is limited evidence to support the use of bone scan as the next imaging study of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. Pretreatment Detection of Prostate Cancer Choline PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/CT for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. Choline PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/MRI for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis With IV Contrast There is limited evidence to support the use of CT abdomen and pelvis with IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis Without and With IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without and with IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically.
Pretreatment Detection Surveillance and Staging of Prostate Cancer. Therefore, in isolation, TRUS is inaccurate for prostate cancer detection and is not beneficial for this purpose [65]. Variant 2: Clinically suspected prostate cancer. Negative TRUS-guided biopsy. Initial diagnosis. Next imaging study. Bone Scan Whole Body There is limited evidence to support the use of bone scan as the next imaging study of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. Pretreatment Detection of Prostate Cancer Choline PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/CT for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. Choline PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of choline PET/MRI for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis With IV Contrast There is limited evidence to support the use of CT abdomen and pelvis with IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis Without and With IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without and with IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically. CT Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of CT abdomen and pelvis without IV contrast for initial imaging of patients with clinically suspected prostate cancer unless or until the presence of higher-risk disease has been established histologically.